ANDA 91464, held by Teva Pharms USA. Solifenacin Succinate.
As of Nov 16, 2026, ANDA 91464 (Solifenacin Succinate), held by Teva Pharms USA, was first approved by FDA on Apr 2, 2014, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 2, 2014 | Original application | Approved |
| Solifenacin Succinate5MG · tablet;oral | Solifenacin Succinate | Rx |
| Solifenacin Succinate10MG · tablet;oral | Solifenacin Succinate | Rx |
| Jan 26, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 20, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 2, 2014 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters